Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Part of paid clinical trials in New York, New York.

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT00082823
Phase
PHASE1
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: This phase I trial is studying the side effects of VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Key Dates

First listed
May 19, 2004
Start date
Jan 31, 2004
Status verified
Jun 2016
Primary completion
May 31, 2008

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
Memorial Sloan - Kettering Cancer CenterNew YorkNew York10021-
Vanderbilt-Ingram Cancer CenterNashvilleTennessee37232-6838-

Find similar trials in New York, NY

By research site
Memorial Sloan - Kettering Cancer Center· New York, NYVanderbilt-Ingram Cancer Center· Nashville, TN

Related Studies